The use of angiotensin-converting enzyme inhibitors in hospitalized patients with COVID-19 is associated with a lower risk of mortality

Mykola Khalangot, Vitaliy Gurianov, Tamara Zakharchenko, Victor Kravchenko, Olena Kovzun, Volodymyr Shupachynskiy, Mykola Tronko · 2025

Read The use of angiotensin-converting enzyme inhibitors in hospitalized patients with COVID-19 is associated with a lower risk of mortality by Mykola Khalangot, Vitaliy Gurianov, Tamara Zakharchenko, Victor Kravchenko, Olena Kovzun, Volodymyr Shupachynskiy, Mykola Tronko (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12749046.txt.

Description

The relationship between the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), diabetes mellitus (DM), and the risk of death in patients with COVID-19 remains controversial. We hypothesized that DM and certain characteristics of the COVID-19 course during hospital treatment may alter the assessment of the association of ACEIs/ARBs with COVID-19 outcomes.

Catalog record

CREATORMykola Khalangot, Vitaliy Gurianov, Tamara Zakharchenko, Victor Kravchenko, Olena Kovzun, Volodymyr Shupachynskiy, Mykola Tronko
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12749046

Browse the full library · About the Tower of Babel